Physician profile
Javier E Sosa
NPI 1194816041
$3,354.64
in general payments reported to CMS, 2019-2025
28 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.74 · 2020: $377 · 2021: $810 · 2022: $346 · 2023: $563 · 2024: $421 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $824.42 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $521.97 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $420.43 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $257.85 | 2021-2023 | Qulipta |
| Amgen INC. | $187.48 | 2020-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $185.54 | 2024-2025 | Intracept, Watchman Flx |
| Lilly USA, LLC | $127.17 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $99.56 | 2020-2024 | Gardasil 9, Gardasil |
| Dexcom, INC. | $96.13 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.48 | 2022-2024 | Xifaxan |
| Pfizer INC. | $84.13 | 2022-2025 | |
| Spinefrontier, INC. | $72.64 | 2025 | Nanofuse, Facetfuse, Inspan |
| Abbott Laboratories | $40.80 | 2023-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $40.70 | 2021 | |
| Astellas Pharma US INC | $37.89 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32.39 | 2019-2020 | |
| Exact Sciences Corporation | $29.83 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $25.20 | 2020 | |
| Sanofi Pasteur INC. | $21.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.49 | 2019 | |
| Hologic Sales and Service, LLC | $19.92 | 2025 | Aptima |
| Novartis Pharmaceuticals Corporation | $18.80 | 2023 | |
| Corcept Therapeutics | $18.26 | 2025 | Korlym |
| Horizon Therapeutics Plc | $17.11 | 2020 | |
| Lundbeck LLC | $17.00 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $16.76 | 2021 | |
| Allergan, INC. | $15.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Sosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.